Nama's AI scorecard currently rates Veradermics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does MANE report earnings?

Veradermics's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.62.

What is the MANE price target?

The median analyst price target from 6 analysts is $171.00, with a range of $135.00 – $204.00.

Is MANE Shariah compliant?

Nama's AAOIFI-style screen reads Veradermics as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Veradermics (MANE)

Healthcare · Biotechnology · NYSE

Veradermics (MANE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $5.80B and a free-cash-flow yield of -1.5%. Nama's AI scorecard rates it Sell, 3.5 out of 10.

AI scorecard

Sell · 3.5/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-5.3%

How far the last close sits under the highest price of the past five years.

Market cap	$5.80B
Trailing P/E	—
Price / book	7.1
Price / sales	—
FCF yield	-1.5%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	—
Exchange	NYSE
Sector	Healthcare
Industry	Biotechnology

MANE earnings

Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$0.62). Beat the EPS estimate in 1 of 2 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 11, 2026	-$0.58	-$0.64	+9.4%	$0
Q4 2025	Mar 30, 2026	-$104.54	-$18.24	-473.1%	$0

MANE analyst price target

Median target $171.00 from 6 analysts, ranging $135.00 – $204.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live MANE data on Nama Insights →

MANE FAQ

Is MANE a buy?: Nama's AI scorecard currently rates Veradermics Sell (3.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MANE report earnings?: Veradermics's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.62.
What is the MANE price target?: The median analyst price target from 6 analysts is $171.00, with a range of $135.00 – $204.00.
Is MANE Shariah compliant?: Nama's AAOIFI-style screen reads Veradermics as Can't Tell. A figure the screen needs is missing, so it can't tell.